Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TArgeting Type 1 Diabetes Using POLyamines (TADPOL): A Randomized, Double-Masked, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Difluoromethylornithine (DFMO) to Preserve Insulin Production in Type 1 Diabetes

NCT05594563 is registered in ClinicalTrials.gov with Emily K. Sims as lead sponsor.

NCT NCT05594563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05594563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TArgeting Type 1 Diabetes Using POLyamines (TADPOL): A Randomized, Double-Masked, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Difluoromethylornithine (DFMO) to Preserve Insulin Production in Type 1 Diabetes
Lead sponsor
Emily K. Sims
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 14, 2023
Completion date
June 30, 2027
Enrollment
74 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes